Type 2 Diabetes | Access and Reimbursement | EU5 | 2016
Type 2 diabetes (T2D) is a chronic metabolic disease affecting more than 28 million people in the five major European pharmaceutical markets (France, Germany, Italy, Spain, United Kingdom; EU5). At the core of T2D treatment is long-generic standard of care metformin (Merck KgaA’s Glucophage, generics) as first-line therapy. However, T2D patients typically require therapeutic intensification, with drugs from several other classes, including DPP-IV inhibitors, SGLT-2 inhibitors, GLP-1 receptor agonists, and insulin analogues competing with generic alternatives for position as second- and third-line therapy status. These branded agents are competing in an increasingly cost-sensitive environment, and marketers need to provide clear evidence of clinical improvements and/or cost benefits on well-defined clinical endpoints over well-entrenched, generically available standards-of-care to ensure favorable health technology assessment (HTA) and favorable pricing and reimbursement terms.
